Fulcrum Therapeutics, Inc. Q3 FY2025 earnings call

• Fulcrum's lead program, pociredir, showed promising results in the Phase Ib PIONEER trial for sickle cell disease, with dose-dependent increases in fetal hemoglobin, improvement in biomarkers, reduced vaso-occlusive crises, and good tolerability.
• Submitted a protocol to the FDA to initiate an open-label extension trial for pociredir.
• Completed enrollment in the 20-milligram dose cohort of the PIONEER trial, with data to be presented at ASH.
• Advancing program for bone marrow failure syndromes, planning to submit an IND in Q4 2025.
• Preclinical data on FTX-6274, an oral EED inhibitor, showed efficacy in castration-resistant prostate cancer models.

For the third quarter ended September 30, 2025, research and development expenses were $14.3 million, down from $14.6 million in the third quarter of 2024. General and administrative expenses were $7.6 million, down from $8.4 million in the prior year. Net loss was $19.6 million, compared to a net loss of $21.7 million in the third quarter of 2024. Cash, cash equivalents, and marketable securities ended the third quarter of 2025 at $200.6 million, down from $241 million as of December 31, 2024. The decrease in cash is primarily due to cash used to fund operating activities.

Based on current operating plans, existing cash, cash equivalents, and marketable securities are expected to fund operating requirements into 2028, providing runway to progress pociredir's clinical development.

Q: Kristen Kluska asks about comparing cohorts and measuring dose response.

A: Alexander Sapir and Iain Fraser discuss handling dose response, baseline characteristics, and data presentation at ASH.

Q: Corinne Johnson asks about 20 mg dose cohort and cash runway.

A: Iain Fraser and Alan Musso respond on efficacy expectations and cash runway scope.

Q: Edward Tenthoff asks about ASH abstracts and final PIONEER data.

A: Alexander Sapir and Iain Fraser talk about abstract content, presentation type, and timeline for final data.

Q: Luca Issi asks about safety follow-up and clinical plan beyond Phase Ib.

A: Iain Fraser discusses safety discussions with FDA and future clinical trial design.